AstraZeneca’s Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to...
Boston Therapeutics begins Phase IIb Sugardown trial for type 2 diabetes patients
US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type...
KIP THE HUMANS: DRUG DISCOVERY BY SIMULATING CELLS
The future of medicine, we're often told, will be personalized. We'll have gene therapies, wearables to monitor our vital signs—maybe even new kinds of...
VA’S CONVOLUTED PATIENT SCHEDULING STARTS WITH A ‘HELPLINE’ CALL
Veterans trying to schedule medical appointments in the Veterans Affairs Department’s Phoenix Health Care System entered a Kafkaesque world where they had to call...
UF Health successfully implements genomic medicine program
GAINESVILLE, Fla. — At the conclusion of the first year of UF Health’s Personalized Medicine Program, the results are in: The program has successfully...
European Commission grants marketing approval for Teva’s DuoResp Spiromax
Teva Pharmaceutical has obtained marketing authorisation approval from European Commission for its DuoResp Spiromax for treatment of patients with asthma and chronic obstructive pulmonary...
Bavarian Nordic doses first patient in Phase II trial of CV-301 to treat bladder cancer
Denmark-based biotechnology firm Bavarian Nordic has dosed first patient in a randomised, prospective Phase II trial of its active immunotherapy product candidate CV-301 for...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...